Collectively, from these experimental results, we identified that serum EV-derived miRNA-105-5p could foster ESCC cell growth in vivo by targeting SPARCL1 and modulating the FAK/Akt signaling pathway. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.